The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration | Zendy

Irmgard Leitner | Zendy; Johannes Nemeth | Zendy; Thomas Feurstein | Zendy; Aiman Abrahim | Zendy; Peter Matzneller | Zendy; Heimo Lagler | Zendy; Thomas Erker | Zendy; Oliver Langer | Zendy; Markus Zeitlinger | Zendy

Open Access

The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration

Author(s) -

Irmgard Leitner,

Johannes Nemeth,

Thomas Feurstein,

Aiman Abrahim,

Peter Matzneller,

Heimo Lagler,

Thomas Erker,

Oliver Langer,

Markus Zeitlinger

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq526

Subject(s) - efflux , ciprofloxacin , stenotrophomonas maltophilia , multiple drug resistance , pseudomonas aeruginosa , p glycoprotein , pharmacology , microbiology and biotechnology , staphylococcus aureus , chemistry , minimum inhibitory concentration , potency , drug resistance , in vitro , biology , antibiotics , biochemistry , bacteria , genetics

The use of efflux pump inhibitors may be a powerful strategy to overcome transporter-mediated bacterial multidrug resistance. In the present study, we set out to investigate the potency of tariquidar, a third-generation P-glycoprotein inhibitor in clinical development, for overcoming bacterial resistance towards ciprofloxacin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research